Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas

Table 4

Ongoing lenalidomide-based regime trials.

Name	Phase	Age	Histology	Drugs	Status
NCT01419795	II	>18 ys	Relapsed or refractory NHL after allo-SCT	RL	Ongoing and recruiting
NCT00238238	II	>18 ys	Relapsed follicular NHL	RL	Ongoing and recruiting
NCT00633594	I/II	>18 ys	Relapsed or refractory MCL	RVL	Ongoing and recruiting
NCT00553644 (27)	II	>18 ys	Relapsed or refractory MCL	LV	Ongoing and recruiting

RL: rituximab, lenalidomide; RVL: rituximab, bortezomib, lenalidomide; LV: lenalidomide, bortezomib.